By using complementary in vitro and ex vivo approaches, we show that the risk allele (Y153H) of the preeclampsia susceptibility gene STOX1 negatively regulates trophoblast invasion by upregulation of the cell -cell adhesion protein a-T-catenin (CTNNA3). This is effectuated at the crucial epithelial -mesenchymal transition of proliferative into invasive extravillous trophoblast. This STOX1 -CTNNA3 interaction is direct and includes Akt-mediated phosphorylated control of nucleo-cytoplasmic shuttling and ubiquitin-mediated degradation as shared with the FOX multigene family. This, to our knowledge, is the first time a genotype associated with pre-eclampsia has been shown to directly limit first trimester extravillous trophoblast invasion, the earliest hallmark of pre-eclampsia.
INTRODUCTION
Recently, we demonstrated STOX1 to be a pre-eclampsia susceptibility gene, in Dutch females (1) . This association is specific for the form of pre-eclampsia with the highest morbidity and mortality, i.e. the familiar form with early-onset, grand-maternal origin and associated intrauterine growth retardation (2) . STOX1 codes for a winged helix protein both structurally and functionally related to the Forkhead (FOX) multigene family. We have previously demonstrated that overexpression of STOX1 in a first trimester extravillous trophoblast cell line, SGHPL-5, resulted in abundant, but inverse, nuclear or cytoplasmic localization in polyploid and diploid cells, respectively (1) . Polyploidization accompanies the transition from invasive to non-invasive behavior in extravillous trophoblasts. In rodent extravillous trophoblasts, polyploidization (giant cells) involves activation of the PI3K-Akt pathway (3) . Secondly, nuclear localization and nuclear export signals (NES) were predicted in exons 1 and 3, respectively (1) . In the FOX multigene family, these dual control sequences, among other factors, regulate nuclear-cytoplasmic shuttling of the FOX proteins (4) . In STOX1, these dual control sequences are present only in isoform A. Accordingly, isoform A was either located in the cytoplasm or nuclei, whereas the shorter isoforms B and C, lacking NES, were found only in the nuclei (1) . Aktphosphorylated FOX proteins are inhibited from entering the nucleus, complex with 14-3-3 proteins and are degraded by ubiquitination (5, 6) . This feature has been demonstrated for several of the class I (A-G, I-L, Q) and II (H, M-P) Forkhead proteins, i.e. FOXN1, FOXA2, FOXD1, FOXC2, including those of the O class (7 -10) , suggesting that STOX1 may be regulated in a similar manner. Thirdly, four missense variations in STOX1 have been identified, identical between pre-eclampsia affected sisters and segregating with the preeclamptic phenotype (1) . The predominant variation (Y153H), located within the winged helix DNA binding domain, is highly mutagenic by conservation criteria, but subject to incomplete penetrance (1) . One or more genes, differentially affected by STOX1, are needed to explain the full pre-eclamptic phenotype. This is in analogy with the FOX proteins of which some, e.g. FOXC1, only cause disease by differential interaction of the wild-type and mutant form with downstream genes (11) .
Candidate genes transactivated by STOX1 in an alleledependent manner are preferentially located within the 10q22 region with linkage and parent-of-origin effect (12) and most probably reduce trophoblast invasion, the initiating point of pre-eclampsia (13) . A candidate is CTNNA3 located on 10q22, imprinted in villous trophoblasts (14) and coding for the cell adhesion complex protein a-T-catenin (15) . In the cell adhesion complex, a-T-catenin associates with Ecadherin which is known to be upregulated in pre-eclamptic placentas (16) (17) (18) (19) and inhibits trophoblast invasion (20) . Moreover, by microarray analysis, CTNNA3 was found to be differentially expressed in STOX1-transfected extravillous trophoblast (M. van Dijk et al., unpublished observations). Finally, a conserved role for STOX1 in cellular migration was proved in Xenopus neural crest cells. Stage 21 embryos injected on one side with STOX1 showed a reduced migration pattern in the neural cleft compared with the control side (21) .
These data led us to hypothesize that STOX1 negatively regulates trophoblast invasion via an effector gene involved in cell -cell adhesion.
RESULTS

STOX1 shows multiple functional similarities to FOX transcription factors
By quantitative RT -PCR analysis of SGHPL-5 cells, transfected with plasmids expressing wild-type (WT) or mutant (Y153H) STOX1 proteins, we found the CTNNA3 gene to be transactivated (Fig. 1A) . The increase in expression was dependent on the STOX1 isoform transfected and the allele carried. Wild-type isoform A induced expression by 2-fold, whereas isoforms B and C did not have any effect. Isoform A showed allele-dependent differences in CTNNA3 transactivation. The increase by mutant isoform A was almost 6-fold, three times higher than the wild-type form. This gain-of-function is allele-specific, and also appears to be cell-type-or gestational age-specific, as none of these effects were seen in 3A cells, a trophoblast cell line obtained from term placenta (Supplementary Material, Fig. 1A) .
Within isoform A, two possible Akt phosphorylation sites on serine residues 647 and 944 were predicted. The serine residues were substituted with either an alanine (A) or glutamic acid (E) to prevent or to mimic phosphorylation, respectively (22, 23) . Initial experiments with all constructs showed the serine mutated at 944 only yielded cytoplasmic expression after transfection, thus the detailed analysis was limited to serine 647. Western blot analysis of cytoplasmic, nuclear and histone fractions demonstrated that expression of the STOX1 WT and S647A proteins was restricted to the nuclear fraction (Fig. 1B) . Phosphorylation of STOX1 by Akt prevents nuclear shuttling, thus cytoplasmic expression of the S647E was expected, but not observed in our experiments. We therefore tested that the construct was transcribed, followed by rapid degradation of the translated protein. Fig. 1C ). Ubiquitin-mediated degradation was confirmed using the ubiquitin inhibitor MG132 and showed that the addition of MG132 resulted in the upregulation of STOX1 expression in the cytosolic fractions (Supplementary Material, Fig. 1D ). Additionally, to confirm that phosphorylation of STOX1 with subsequent cytoplasmic to nuclear translocation involves the PI3K-Akt pathway, a PI3K inhibitor (LY294002) was added to STOX1A WT transfected cells. This resulted in an increase in STOX1 expression in the nuclear fractions, whereas a decrease in expression was seen in the cytosolic fractions (Supplementary Material, Fig. 1E ). Expression of CTNNA3, transactivated by STOX1, was also measured comparing wildtype STOX1 against the S647A and S647E constructs. In accordance with the exclusion of phosphorylated STOX1 from the nucleus, CTNNA3 expression was significantly decreased following transfection with the S647E construct (Fig. 1C) . The small, but significant, decrease in expression after transfection with the S647A construct indicates the functional importance of this amino acid.
The effect of STOX1 on CTNNA3 expression is direct, as chromatin immunoprecipitation (ChIP) followed by quantitative PCR of the CTNNA3 promoter region showed a 1.8-fold enrichment of CTNNA3 -promoter DNA bound to WT STOX1 when compared with its negative control (Fig. 1D) . The enrichment obtained with the STOX1 Y153H protein was 20.8-fold, indicating that the binding of STOX1 Y153H to the CTNNA3 promoter is much stronger, as expected with a 3-fold increase in the mRNA expression level.
STOX1 negatively regulates SGHPL-5 invasion
Matrigel invasion assays were performed using the SGHPL-5 extravillous trophoblast cell line. SiRNA-mediated downregulation of STOX1A or a-T-catenin significantly increased the number of invaded cells on the underside of the membrane ( Fig. 2A) . In contrast, transient overexpression of a-T-catenin or WT STOX1A recombinant proteins reduced SGHPL-5 invasion, an effect that was enhanced on the addition of the STOX1 Y153H protein. When STOX1A is downregulated in combination with overexpression of a-T-catenin, the effects of the STOX1 siRNAs are reduced. This is not seen when overexpression of STOX1A is accomplished in combination with downregulation of a-T-catenin, confirming that the effects on invasion of SGHPL-5 cells observed are caused by a-T-catenin as an effector gene of STOX1A. Migration assays without a Matrigel barrier were used for immunostaining the inside and the underside of the membrane. Migration was accompanied by a decrease in proliferative activity [KI67 expression (Fig. 2B) ]. STOX1 immunostaining on the inside was detected in nuclei and cytoplasm, whereas STOX1 staining on the underside was only visible in the cytoplasm of migrated cells, indicative of phosphorylation and thus inactivation of the protein. a-T-catenin expression was cytoplasmic in non-migrated cells, but completely lost after the cells had migrated through the membrane.
Silencing of STOX and CTNNA3 leads to increased extravillous trophoblast outgrowth
We next used the ex vivo villous explant model to confirm that the STOX1-mediated reduction in SGHPL-5 trophoblast invasion via a-T-catenin upregulation also occurred in the first trimester placenta. Pictures of the explants were taken at Day 2 and Day 4 after which the change in length of trophoblast outgrowth was measured (Supplementary Material, Fig. 2 ). Explants subjected to siRNA-mediated STOX1 or a-T-catenin inhibition showed a significant increase in outgrowth (Fig. 3A) . In non-silenced explants both STOX1 (Fig. 3B ) and a-T-catenin (Fig. 3C ) localized to the proliferative column extravillous trophoblasts. No a-T-catenin expression was detected in the distal invasive extravillous trophoblasts (Fig. 3C , small arrow). Silencing of STOX1 reduced the nuclear expression of STOX1 with the remaining protein localized mainly in the cytoplasm (Fig. 3C ). Transactivation of a-T-catenin by STOX1 was confirmed by decreased a-T-catenin immunoreactivity in the column extravillous trophoblasts of the STOX1 siRNA-treated explants (Fig. 3C ). In accordance with our findings in SGHPL-5 cells, the column extravillous trophoblasts in explants treated with either STOX1 or CTNNA3 siRNAs showed a significant decrease in proliferation, measured by the number of Ki67-positive cells, compared with their controls (Fig. 3D ). Similar results were observed when counting the phospho-histone-H3-positive (mitotic) cells (data not shown). These data confirm that silencing of STOX1 or CTNNA3 leads to a change in extravillous trophoblast phenotype toward a non-proliferative cell type in the early placenta.
Outgrowth of villous explants and CTNNA3 expression in the floating explant model correlates with STOX1 genotype
To assess whether these changes were also allele dependent with a gain-of-function of the mutant allele, we genotyped the explants and quantified the mRNA expression of STOX1 and CTNNA3. A significant difference was found with a decreased outgrowth in explants carrying the HH genotype compared with the wild-type YY genotype (Fig. 4A) . No significant differences were found in CTNNA3 expression despite a trend toward higher expression in the YY genotypes Fig. 3A) . However, linear regression analysis revealed a significant correlation between CTNNA3 and STOX1 expression in the HH genotype, while no such effect was seen in the YY (wild-type) genotype (Fig. 4B) . These data confirm that the transactivation effects of STOX1 on CTNNA3 are cell-type specific. The genotype accounts for differences in trophoblast outgrowth and responsiveness of CTNNA3 expression to increased levels of STOX1, whereas the absolute differences in mRNA expression are masked by the expression of CTNNA3 in other cell types within the villous explant. This possibility was investigated further using the floating villous explant model. In this model, villi without extravillous trophoblast cell columns are dissected and either treated with trypsin (to remove the syncytial layer), treated with FGF4 and heparin, or subjected to both treatments. Syncytial denudation alone leads to reformation of this layer after 3 days, while treatment with FGF4 alone leads to cytotrophoblast proliferation. When explants are first denudated and subsequently treated with FGF4, instead of syncytial growth, a proliferating extravillous trophoblast cell column is formed (24) . The CTNNA3 mRNA expression now showed clear differences in expression between the three sets of differently treated explants (Fig. 4C ). Samples treated with either trypsin or FGF4 alone showed higher CTNNA3 expression in YY explants, whereas the samples treated with both trypsin and FGF4, thereby giving rise to trophoblast columns, showed the complete opposite; higher CTNNA3 expression in HH explants compared with the YY genotype. These data confirm the cell-type (column extravillous trophoblast) specificity of the transactivation effect of STOX1 on CTNNA3 expression.
CTNNA3 expression changes towards higher expression in column extravillous trophoblasts with Y153H genotype
To validate this conclusion, we next microdissected the columns from the tips of placental villi to yield a population of column extravillous trophoblasts with a small piece of villous still attached to it. Although this does not yield a pure population of column extravillous trophoblasts, the floating explant experiments showed that the effects can be seen with other cells present. CTNNA3 and STOX1 mRNA expression levels correlated with gestational age. A significant linear correlation was seen between advancing gestational age and higher expression of these genes ( Fig. 5A and B) . Due to the number of samples preventing individual comparison at each gestational week, a smaller gestational age window (8 -13 weeks) was selected and samples of different gestational ages were pooled for comparison. CTNNA3 mRNA expression now showed an increase in STOX1 HH genotypes compared with YY, as was seen in the floating explant model treated with both trypsin and FGF4 ( Supplementary  Material, Fig. 3B ). The expression level of STOX1 mRNA did not show a difference between YY and HH (data not shown). When CTNNA3 expression was plotted against STOX1 expression, the YY genotype showed no effect on CTNNA3 expression upon increased STOX1 expression, while for the HH genotype increased STOX1 expression correlated with increased CTNNA3 expression with a similar slope as that observed in the explants on Matrigel (Fig. 5C ). When STOX1 downregulation is combined with a-T-catenin upregulation, the effects of the siRNAs are reduced. This is not observed when STOX1 upregulation is combined with a-T-catenin downregulation. Bars are mean + SEM. a is P , 0.05, b is P , 0.001, c is P , 0.01 compared with mock in combination with scrambled siRNAs transfection (t-test). d is P , 0.05 compared with mock with STOX1 siRNAs transfection; e is P , 0.001 compared with WT STOX1 with scrambled siRNAs transfection; f is P , 0.001 compared with Y153H STOX1 with scrambled siRNAs transfection (t-test). (B) KI67, STOX1 and a-T-catenin staining on non-migrated (inside well) and migrated (underside well) SGHPL-5 cells. A decrease of proliferation after migration can be detected with a shift toward sole cytoplasmic expression of STOX1 and loss of a-T-catenin expression.
DISCUSSION
Here we show, for the first time, using complementary in vitro and ex vivo approaches, that the STOX1A 153H genotype, associated with the form of pre-eclampsia with highest morbidity and mortality, leads to a cell-specific and allele-dependent pathophysiological reduction in extravillous trophoblast invasion, the earliest hallmark of pre-eclampsia. The default situation involves direct binding and transactivation of the promoter of the cell -cell adhesion complex protein a-T-catenin by unphosphorylated (active) nuclear STOX1A. This process involves a feedback loop shared with the FOX multigene family with Akt-mediated phosphorylated control of nucleo-cytoplasmic shuttling and ubiquitin-mediated degradation of STOX1. However, STOX1 does not contain the consensus sequence (RxRxxS/T), but the variant PxRxxS with a proline-replacing arginine at the first position as described for Pak1 (25) . Other factors in this feedback loop that lead to strengthening or weakening of the cell -cell adhesion complex by phosphorylation of Akt are probably mediated by b-catenin and MAGI-1/2b (26, 27) . When cell -cell adhesion is reduced, the reduction in Akt-mediated effects on STOX1 allows re-accumulation of STOX1 in the nucleus where it can again increase a-T-catenin expression. In this way, STOX1 mediates a balance of proliferation versus invasion via cellcell adhesion in the extravillous trophoblast cell column. The effects are specific for extravillous trophoblasts, as seen in the SGHPL-5 cell line and ex vivo column extravillous trophoblasts, while they have not been found in the 3A cytotrophoblast cell line nor in other cells of the placental explants. Besides specific for extravillous trophoblasts, STOX1 control of invasion by regulating a-T-catenin expression appears to act at a specific transition point in the process of extravillous trophoblast differentiation in the anchoring cell column, i.e. the crucial process of epithelial -mesenchymal transition of proliferative zone I extravillous trophoblasts into invasive distal zone II and interstitial zone III extravillous trophoblasts. This is phenotypically accompanied by decreased a-T-catenin expression, decreased proliferation (KI67), and a change to cytoplasmic location of phosphorylated (inactive) STOX1A. As expected, silencing of either STOX1 or CTNNA3 leads to increased extravillous trophoblast invasiveness. Accordingly, explants carrying the 153H genotype showed significantly reduced outgrowth, and an increased responsiveness of CTNNA3 expression upon increased STOX1 expression when compared with 153Y (wild-type). Clinically, the situation can be explained by the gain-of-function of the 153H STOX1 allele where the endophenotype, i.e. reduced invasion, follows an increased a-T-catenin expression. We want to emphasize that the STOX1 153H allele is essential, but not sufficient, for explaining the complete pre-eclampsia phenotype, one or more other genetic variations are required. In this respect, it is interesting to test whether genes such as the ACVR2A gene, associated with pre-eclampsia in the Norwegian population and located on chromosome 2q22 (28) or CTNNA2, associated with the Icelandic population and located in the 2p12 region (29) qualify as genes involved in STOX1 -a-T-catenin controlled extravillous trophoblast differentiation. Furthermore, we want to stress that genetic variations in heterogenous multivariant diseases like pre-eclampsia can only be identified when the population or cohort studied is very homogenous in phenotype, as otherwise associations are missed (30, 31) .
To summarize, we have shown that STOX1 negatively regulates trophoblast invasion and maintains proliferation in both SGHPL-5 cells and villous explants. We have shown that STOX1 binds to the CTNNA3 promoter increasing the expression of a-T-catenin, a component of the cell -cell adhesion complex. Moreover, we have shown that villous explants carrying the STOX1 HH allele, which is associated with pre-eclampsia, have a reduced trophoblast outgrowth and an induced responsiveness of CTNNA3 expression upon STOX1 expression. These data are therefore consistent with a model in which the HH allele of STOX1 is associated with an increased cell -cell adhesion and reduced differentiation into the invasive phenotype.
In conclusion, to our knowledge, this is the first time a genotype linked to pre-eclampsia, i.e. STOX1 Y153H, has a demonstrated effect on extravillous trophoblast invasion, central in the etiology of pre-eclampsia. These data provide a further understanding on the regulation of trophoblast invasion and permit detailed exploration of the pathways that operate early in the pathogenesis of pre-eclampsia.
MATERIALS AND METHODS
Quantitative RT-PCR on transfected SGHPL-5 and 3A cell lines
Plasmids coding for EGFP-STOX1 isoforms A, B and C were constructed as described. The mutant variants, Y153H, S647A and S647E, were made using the QuickChange Site-Directed Mutagenesis kit (Stratagene). These constructs were transfected into SGHPL-5 cells and 3A cells by lipofection using FuGene HD (Roche). The SGHPL-5 cell line represents normal diploid extravillous trophoblasts generated from first trimester placenta by SV40 immortalization (32) . The 3A cell line (CRL-1583) is a hypodiploid trophoblast cell line generated from term placenta by SV40 transformation (33) . At the non-permissive temperature (408C), these cells express the non-transformed phenotype with normal placental functions (hCG and alkaline phosphatase synthesis), therefore cell culture of the 3A cell line was performed at 408C. Protein expression after transfection was confirmed on glass coverslips [Supplementary Material, Fig. 4, ref. (1)] and western blots stained with GFP antibody (Fig. 1B, Supplementary Material,  Figs 1B and 4) . RNA isolation from transfected cells was performed using the RNeasy kit, including DNase treatment (Qiagen). For CTNNA3 transcript quantification, a first round of RT -PCR was performed using the Superscript II One
Step RT-PCR system (Invitrogen) with the inclusion of 1 M betaine performed for 15 cycles. Subsequently, amplified cDNA (1 ml) was quantified using standard real-time PCR methods on an ABI7300 using Taqman probes in the presence of 1 M betaine and ROX reference dye. All quantitative measurements were corrected for RNA input by measuring PBGD as described (34) . In addition, transfection effiencies were corrected by plasmid DNA quantification using the GFP backbone present in all plasmids. Primer and probe sequences and PCR characteristics are available upon request. Data are obtained from four transfections from which each RNA sample in triplicate was measured twice.
STOX1 phosphorylation by Akt
Protein lysates from transfected cells were generated by either using Qproteome Nuclear Protein kit (Qiagen) to obtain different fractions or by directly scraping cells into loading buffer, including DTT. The lysates were separated by (SDS) sodium dodecyl sulphate -polyacrylamide gel electrophoresis, and blotted onto a polyvinylidene fluoride (PVDF) membrane. An antibody recognizing GFP-protein (Cell Signaling) was used in combination with goat anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody (DAKO). Protein bands were detected by an enhanced-chemiluminescence assay (GE Healthcare) on an LAS3000. Loading controls were performed using GAPDH antibody (Cell Signaling), RNA polymerase II antibody (Upstate) or acetylated histone H3 K9K14 antibody (Abcam) for detection in the cytoplasmic, nuclear or histone fraction, respectively. To obtain information on the mRNA expression of the plasmid, RT-PCR was performed on RNA from cells transfected with WT, S647A or S647E constructs using the Superscript II One Step RT-PCR system with the inclusion of 1 M betaine. The primers used covered the S647 location within STOX1. Also reactions omitting Reverse Transcriptase were taken along to be certain not to obtain amplified plasmid DNA. The PCR products were analyzed by DNA sequencing, using the reverse primers with Big Dye Terminators followed by separation on an ABI3130xl genetic analyzer.
Chromatin immunoprecipitation
For the ChIP, the Halo-ChIP system (Promega) was used. For this, the STOX1A gene (WT and Y153H) was subcloned into pFN21A (Halotag 7) CMV Flexi vector (Promega) and transfected into SGHPL-5 cells, after which the protein expression and equal transfection efficiencies of the STOX1A-Halotag proteins were confirmed on glass coverslips using the TMR-Halotag ligand (Promega) for visualization. The cells were treated with formaldehyde to create protein -DNA crosslinks and subsequently lysed. The lysates were split into two equal parts, of which one was treated with Halotag-blocking ligand, to function as a negative control. Both the samples and controls were treated using Halotag resin according to the Halo -ChIP system protocol. After reversal of crosslinks, the DNA was purified using the Qiaquick PCR purification kit (Qiagen). A standard real-time PCR was performed on an ABI7300 using Taqman probes (sequences available upon request) specific for the CTNNA3 promoter (35) in the presence of 1 M betaine and ROX reference dye, and corrected for input using the non-intron-spanning GAPDH gene expression assay (Applied Biosystems). The experiments were repeated at least three times.
Migration and invasion assay
In the migration assay, the SGHPL-5 cell line was transfected with either scrambled siRNA or siRNAs against STOX1 or CTNNA3 (siRNA sequences available upon request) and EGFP-a-T-catenin (a kind gift of Dr. F. van Roy) or EGFP-STOX1 constructs using FuGene HD transfection reagent (Roche). Transfection efficiencies of EGFP plasmids were monitored in culture; siRNA knockdown ( 50%) was regularly assessed by quantitative RT -PCR on RNA from transfected cells. Transfected cells were serum starved for 24 h after which 100 000 cells were plated on fibronectincoated 8.0 mm cell culture inserts and migrated for 24 h.
Total transfection time was either 96 h (siRNAs) or 72 h (recombinant proteins). The insert membranes were fixed, stained with Diff-Quik stain set (Dade Behring) and coverslipped. Four random fields of migrated cells per insert were counted. The invasion assay was performed similarly except that the membranes were coated with 100 ml diluted Matrigel (Becton Dickinson) with 300 000 plated cells, the cells invaded for 48 h after which the whole membrane was counted. The outsides or insides of the membranes in both assays were fixed with 4% (PFA) paraformaldehyde with 1% triton-X100 for use in immunofluorescence. Membranes were blocked for autofluorescence using Sudan Black and for non-specific binding in serum-free protein block (Dako). Primary antibodies were incubated for 1 h at room temperature (RT). Cy3-or Cy5-labeled secondary antibodies were used, followed by (DAPI) 4',6-diamidino-2-phenylindole nuclear stain and mounting in glycerol. Data are obtained from at least three independent experiments.
Tissue collection
First trimester placentas were obtained at the time of elective terminations of pregnancy. Informed consent was obtained from each patient and collections were approved by the Mount Sinai Hospital's Review Committee on the Use of Human Subjects. Tissue was collected into ice-cold (PBS) phosphate buffered saline for villous explant culture.
Villous explants on matrigel
Small fragments of placental villi from 6 to 9 week gestation were dissected from the placenta and placed on culture dish inserts coated with 200 ml Matrigel. Placental villous explants were cultured for a total of 7 days at 3% O 2 and 378C in serum-free Dulbecco's Modified Eagle Medium (DMEM)/ F12 media. Transfection with siRNAs against STOX1 or CTNNA3 or scrambled siRNA using lipofectamine 2000 transfection reagent took place at Day 2 and 4. siRNA knockdown was regularly assessed by quantitative RT -PCR on RNA from explants and found to be around 30%; this is most probably an underestimate as siRNAs reach only the outer layers of tissue, i.e. syncytium and newly formed column extravillous trophoblasts (36) . Also at Day 2 and 4, pictures of the explants were taken to measure changes in outgrowth. At Day 7, the explants were fixed and processed for immunohistochemistry (At least seven different placentas were used for the analyses). In immunohistochemistry antigen retrieval was performed using either microwave pre-treatment in sodium citrate buffer or using 0.125% trypsin at 378C for 10 min. Slides were blocked for peroxidase activity in 0.3% H 2 O 2 and for non-specific binding in serum-free protein block. Primary antibodies were incubated overnight at 48C. Biotinylated secondary antibodies were used, followed by streptavidin -HRP and final staining was done using diaminobenzadine and counterstained using hemotoxilin. To identify extravillous trophoblasts and proliferating cells, sequential sections were stained with HLA-g and Ki67 antibodies, respectively (Supplementary Material, Fig. 5 ). When using the explants for STOX1 genotype experiments, RNA was isolated using the RNeasy plus kit (Qiagen). cDNA was formed using random hexamers in the Multiscribe reverse transcriptase kit (Applied Biosystems), followed by quantitative real-time PCR on a Mastercycler ep Realplex 2 using iTaq SYBR Green Supermix (Bio-rad) to quantify GAPDH (primer sequences available upon request), or standard PCR buffers with Taqman primers and probes for the quantification of STOX1 and CTNNA3. The explant outgrowths were measured by taking the difference of the distance the extravillous trophoblasts migrated between Day 2 and 4. From each placenta (n ¼ 83), at least three explants were grown, explants that did not show any growth were left out of the analyses because they were either not viable or were not properly dissected.
Floating villous explants and column extravillous trophoblasts
Small fragments of villi were dissected from pregnancies of 10-13 weeks gestation (n ¼ 22). The stems were pushed into the underside of a sterile 0.5 cm 3 polystyrene cube. When using trypsin treatment, the explants were transferred to tissue culture wells containing PBS containing 0.125% trypsin for 5 min at 378C. Trypsin digestion was terminated by transferring the cubes through three washes of PBS with 10% (FBS) fetal bovine serum. The explants were cultured in serum-free media (DMEM/F12) with 1% liquid media supplement ITS + 1 (Sigma) at 8% O 2 and 378C. In case of FGF4 treatment of the explants, 25 ng/ml FGF4 (R&D) with 1 mg/ml heparin sodium (Fisher) was added to explant culture wells 24 h after trypsin digestion. After a total of 72 h of culture, the explants were frozen at 2808C. To obtain column extravillous trophoblasts, the columns from placental villi were dissected from pregnancies of 6 -13 weeks gestation (n ¼ 58). These columns, which also contain a small part of villous dissected with it, were also frozen at 2808C. Both the floating explants as well as the columns were processed similarly as the frozen explants on Matrigel.
Genotyping of placental samples
From each placenta used in STOX1 genotype experiments, a small piece of placenta was frozen, of which DNA was isolated using the DNeasy blood & tissue kit (Qiagen). A standard PCR was performed on the genomic area covering the Y153H mutation. After purifying the PCR product using the Purelink kit (Invitrogen), the samples were sequenced by ACGT Corp., Toronto, Canada. After genotyping, placental samples showed normal Mendelian distribution of Y153H genotypes, i.e. 25% YY, 50% YH and 25% HH.
